Drug General Information |
Drug ID |
D0R6OM
|
Former ID |
DIB008621
|
Drug Name |
ACTB-1003
|
Synonyms |
Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Investigative |
[1]
|
Company |
Bayer AG
|
Structure |
|
Download
2D MOL
3D MOL
|
Target and Pathway |
Target(s) |
FGF-3 receptor |
Target Info |
Inhibitor |
[2]
|
Fibroblast growth factor receptor 2 |
Target Info |
Inhibitor |
[3]
|
Ribosomal protein S6 kinase |
Target Info |
Inhibitor |
[1]
|
FGF-4 receptor |
Target Info |
Inhibitor |
[4]
|
Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[5]
|
KEGG Pathway
|
MAPK signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Signaling pathways regulating pluripotency of stem cells
|
Regulation of actin cytoskeleton
|
Pathways in cancer
|
MicroRNAs in cancer
|
Bladder cancer
|
Central carbon metabolism in cancerhsa04010:MAPK signaling pathway
|
Prostate cancer
|
Central carbon metabolism in cancerhsa04012:ErbB signaling pathway
|
HIF-1 signaling pathway
|
mTOR signaling pathway
|
AMPK signaling pathway
|
TGF-beta signaling pathway
|
Fc gamma R-mediated phagocytosis
|
Insulin signaling pathway
|
Proteoglycans in cancer
|
Acute myeloid leukemia
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
Regulation of actin cytoskeletonhsa04010:MAPK signaling pathway
|
Adherens junction
|
Melanoma
|
Central carbon metabolism in cancer
|
NetPath Pathway
|
IL1 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
PANTHER Pathway
|
FGF signaling pathwayP00021:FGF signaling pathwayP00032:Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
PDGF signaling pathway
|
PI3 kinase pathway
|
p53 pathway by glucose deprivation
|
CCKR signaling map STP00021:FGF signaling pathwayP00005:Angiogenesis
|
FGF signaling pathway
|
Pathway Interaction Database
|
FGF signaling pathwayinsulin_pathway:Insulin Pathway
|
IL4-mediated signaling events
|
CDC42 signaling events
|
Angiopoietin receptor Tie2-mediated signaling
|
Regulation of Telomerase
|
mTOR signaling pathway
|
IGF1 pathway
|
IL2 signaling events mediated by PI3K
|
Integrins in angiogenesis
|
RXR and RAR heterodimerization with other nuclear receptor
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
a6b1 and a6b4 Integrin signaling
|
TGF-beta receptor signalingfgf_pathway:FGF signaling pathwayglypican_1pathway:Glypican 1 network
|
Syndecan-4-mediated signaling events
|
N-cadherin signaling events
|
FGF signaling pathway
|
PathWhiz Pathway
|
Leucine Stimulation on Insulin Signaling
|
Reactome
|
FGFR3 mutant receptor activationR-HSA-2033519:Activated point mutants of FGFR2R-HSA-166208:mTORC1-mediated signallingR-HSA-109704:PI3K Cascade
|
PIP3 activates AKT signaling
|
FGFR4 ligand binding and activation
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Phospholipase C-mediated cascade
|
FRS-mediated FGFR4 signaling
|
SHC-mediated cascade:FGFR4
|
PI-3K cascade:FGFR4
|
Negative regulation of FGFR4 signaling
|
RAF/MAP kinase cascade
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
Endochondral Ossification
|
Bladder Cancer
|
Neural Crest Differentiation
|
Signaling by FGFRWP51:Regulation of Actin Cytoskeleton
|
Ectoderm Differentiation
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Cardiac Hypertrophic Response
|
Signaling Pathways in Glioblastoma
|
Signaling by FGFR
|
MicroRNAs in cardiomyocyte hypertrophy
|
AngiogenesisWP673:ErbB Signaling Pathway
|
Interferon type I signaling pathways
|
G13 Signaling Pathway
|
IL-2 Signaling Pathway
|
Insulin Signaling
|
Cytoplasmic Ribosomal Proteins
|
EGF/EGFR Signaling Pathway
|
IL-4 Signaling Pathway
|
IL-6 signaling pathway
|
Kit receptor signaling pathway
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
BDNF signaling pathway
|
Interleukin-11 Signaling Pathway
|
FSH signaling pathway
|
Leptin signaling pathway
|
TSH signaling pathway
|
Signaling by Insulin receptor
|
TOR Signaling
|
AMPK Signaling
|
IL-5 Signaling PathwayWP51:Regulation of Actin Cytoskeleton
|
PIP3 activates AKT signaling
|
MAPK Signaling Pathway
|
Mesodermal Commitment Pathway
|
Integrated Pancreatic Cancer Pathway
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1525). |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810). |
---|
REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809). |
---|
REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811). |
---|
REF 5 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). |